Bristol Myers Squibb stock holds near a $10.7 billion market cap

Bristol Myers Squibb (US0897961004) stock is anchored by $48.3 billion in 2025 revenue, $10.7 billion in net income, and a market capitalization of about $10.7 billion, giving the shares a clear financial backdrop even without a fresh company release in the material available here.

2025 numbers still matter

The company reported $48.3 billion in revenue for 2025, compared with $45.0 billion in 2024, which shows a year-over-year increase of $3.3 billion. Net income reached $10.7 billion in 2025, reversing the $8.9 billion net loss reported in 2024, a swing that remains central to any valuation discussion.

Adjusted earnings per share for full-year 2025 came in at $3.74, while 2026 guidance calls for adjusted EPS of $6.70 to $7.00. That guidance range gives the stock a second reference point beyond the historical income recovery and makes the next reporting cycle more important than simple product headlines.

Guidance points to margin focus

Management has framed 2026 around adjusted EPS rather than a pure revenue narrative, and the guidance implies a much stronger earnings base than the 2025 figure. For investors, the comparison between $3.74 in 2025 adjusted EPS and the $6.70 to $7.00 range for 2026 is the clearest quantified lens on the story.

The 2025 revenue base of $48.3 billion also sits well above the 2024 level of $45.0 billion, so the key question is no longer only top-line scale. It is whether earnings power can keep pace with that larger sales base over 2026.

Product mix still drives cash flow

Bristol Myers Squibb's portfolio remains the main reason the company can translate revenue into earnings, with the 2025 net income figure showing how much operating leverage is left in the business. The improvement from a $8.9 billion net loss in 2024 to $10.7 billion of net income in 2025 is the kind of comparison that usually matters more to the market than a broad description of the pipeline.

The 2026 EPS range of $6.70 to $7.00 suggests that cost discipline and product contribution will stay in focus through the year. That is the number to watch alongside the 2025 revenue and profit base, because the gap between sales growth and earnings growth often tells the fuller story for large pharmaceutical groups.

2025 revenue versus 2024

The headline operating comparison remains straightforward: $48.3 billion in revenue in 2025 versus $45.0 billion in 2024, plus a return to $10.7 billion in net income after the 2024 loss. Those three figures, taken together, show why the stock cannot be read through product headlines alone.

The 2026 guidance range of $6.70 to $7.00 for adjusted EPS adds a forward marker that is numerically stronger than the 2025 result. In practice, that puts earnings execution at the center of the Bristol Myers Squibb stock narrative.

Portfolio size and execution

Bristol Myers Squibb's product mix matters because it determines how much of the $48.3 billion revenue base turns into profit. The 2025 net income of $10.7 billion indicates that the company has already restored a much healthier earnings profile than it had in 2024.

For a large-cap drugmaker, that matters as much as pipeline commentary. A business that can move from a $8.9 billion loss to $10.7 billion of net income in one year has already done the heavy lifting on the financial side, and the next step is sustaining that momentum through 2026.

Stock level and market value

The available market anchor here is the company's roughly $10.7 billion market capitalization. That is far smaller than the 2025 revenue base of $48.3 billion, which means the relationship between enterprise expectations and earnings delivery stays critical for the stock.

Without a fresh quote in the material available here, the most useful market framing is the market-cap-to-income comparison itself. A company with $10.7 billion of net income in 2025 and a roughly $10.7 billion market capitalization offers a compact way to think about how much of the profit recovery may already be reflected in market value.

Investors watch EPS

The product story only matters insofar as it supports the numbers. Bristol Myers Squibb's 2025 adjusted EPS of $3.74 and 2026 guidance of $6.70 to $7.00 give the cleanest bridge between last year's result and this year's expectations.

The stock narrative therefore rests on execution, not on slogans. Revenue of $48.3 billion, net income of $10.7 billion, and the 2026 EPS range together define the reference points that matter most now.

Company profile

Bristol Myers Squibb is a global biopharmaceutical company whose financial profile is currently better captured by revenue, profit, and guidance than by a single headline product. The 2025 result set shows a business that moved from a loss in 2024 to a large net profit in 2025, while 2026 guidance suggests another step up in earnings.

Trading snapshot

Bristol Myers Squibb stock is best read today through its 2025 numbers and 2026 guidance: $48.3 billion revenue, $10.7 billion net income, and adjusted EPS guidance of $6.70 to $7.00. The market value referenced here is about $10.7 billion, which keeps the profit conversion story at the center of the stock case.